Wynn Resorts, Limited (WYNN): Hedge Funds Taking Some Chips Off The Table

Gilead Falls as Drug Has Only Small Benefit in Large Trial

(Bloomberg) -- Gilead Sciences Inc.’s drug remdesivir showed only a limited benefit in a large trial of more moderate patients with Covid-19, a result that may shift perceptions of the therapy already cleared for use in severe cases of the disease.In the phase 3 trial, a group of moderately ill, hospitalized patients getting the drug for five days showed a modest improvement compared to those getting the standard of care, the company said in a statement. But another group getting the drug for 10 days didn’t show a statistically significant improvement, which is likely to raise questions about why a longer course doesn’t help more. Severely ill patients weren’t included in the trial.The shares fell 2.8% to $75.68 at 9:36 a.m. in New York. They’re up 16% this year, largely on optimism around remdesivir. Gilead’s drug has become a symbol of efforts to reopen the economy and effectively treat patients stricken...

Embraer says China, India are potential partners after failed Boeing deal

Brazil's Embraer SA said on Monday that China and India could be potential new partners, following a Reuters report last week that said those two countries as well as Russia were interested in the planemaker's commercial jets division. Embraer is dealing with the abrupt collapse of a planned deal with Boeing Co in April that left the company scrambling for a plan B. Embraer Chief Executive Francisco Gomes Neto said in an earnings call that it was still early to discuss new opportunities in detail as the company is studying a new five-year plan....